Clinical Trial Results: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine [Phase 2]

View source ↗

Summary

Phase IIb trial results for Elismetrep (K-304) in migraine showed outcomes from a randomized, double-blind, placebo-controlled study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Elismetrep

Snippet

Sponsor: Kallyope Inc. | Conditions: Migraine | Phase 2 | Status: COMPLETED | Results posted: 2026-08-27